Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 74Myeloid 32Lymphoid 11Head & Neck 5Other solid neoplasm 4Dermatologic 4Thoracic 3Sarcoma 3Gynecologic 2Gastrointestinal 2CNS 2Breast 2Tumor-Agnostic 1Plasma cell 1Other neoplasm 1Genitourinary 1Classical hematology 1

Conditions

Urinary Bladder Neoplasms 1Melanoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Decitabine × Genitourinary × Clear all
NCT00030615 2013-02-07

Decitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
BreastDermatologicGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡